Press Releases Portage Biotech Inc.

Equities

PRTG

VGG7185A1286

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-13 EDT			5-day change	1st Jan Change
0.2699 ^USD	+6.98%		-11.71%	-85.17%

04-15	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI
04-12	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Portage Biotech : Director Resignations - Form 6-K	05-02	PU
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives-Adenosine clinical development paused	04-15	AQ
Portage biotech announces plans to expand its evaluation of strategic alternatives	04-15	AQ
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives	04-12	AQ
Portage biotech completes monetization of intensity therapeutics shares	03-27	AQ
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	03-26	AQ
Portage Biotech : Corporate Presentation - March 2024	03-07	PU
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update	02-28	AQ
Portage Biotech Reports Business and Strategic Update	01-04	AQ
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update	11-28	AQ
Portage biotech presents updates on its inkt and adenosine programs at the society for immunotherapy of cancer's 38th annual meeting	11-07	AQ
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	11-06	AQ
Portage biotech announces $6.0 million registered direct offering	23-10-02	AQ
Portage Biotech Announces $6.0 Million Registered Direct Offering	23-09-29	AQ
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference	23-09-20	AQ
Portage Biotech : Corporate Presentation - September 2023	23-09-08	PU
Portage biotech announces collaboration with merck to evaluate two next-generation adenosine antagonists in combination with keytruda in solid tumors	23-09-06	AQ
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors	23-09-05	AQ
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update	23-08-30	AQ
Portage Biotech : NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	23-08-29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Portage Biotech Inc.

Equities

PRTG

VGG7185A1286

Press Releases

Filters